Navigation Links
Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

SAN DIEGO, Jan. 30 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008 at 9:20 a.m. Eastern Time (6:20 a.m. Pacific Time) at the Grand Hyatt Hotel in New York City. Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief Scientific Officer, is scheduled to provide an overview of the company, including its clinical development and discovery programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, planned clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications

Arena Pharmaceuticals, Inc.

858.453.7200, ext. 1682

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
3. Arena Pharmaceuticals Announces Public Offering of Common Stock
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. Amylin Pharmaceuticals Reports 2007 Financial Results
8. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
9. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
10. Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Tevas Launch of Generic Pantoprazole
11. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... The recently published ... Data System (NPDS) reveals that in 2014, someone called a poison center about ... million of which were human exposure cases. , The American Association of Poison ...
(Date:11/30/2015)... ... November 30, 2015 , ... Brenntag Specialties, ... channel partner for the Nutraceutical Specialties products into oral solid dosage in the ... , “We are pleased to announce our expanded distribution agreement with ASI.” ...
(Date:11/30/2015)... ... November 30, 2015 , ... Medicalis, a leading ... Society of North America (RSNA) annual meeting, being held November 29 – December ... Throughout 2015, the company has completed installations for Integrated Delivery Network (IDN) ...
(Date:11/30/2015)... FLorida (PRWEB) , ... November 30, 2015 , ... ... PLLC (“Holcomb – Kreithen”), one of the leading plastic surgery practices in Florida, ... has been chosen to consult for surgical innovations giant Ethicon Inc., a Johnson ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, Inc. and Novus ... technology for soft tissue repair in the US via Insightra’s national direct sales ... mesh intended to support and reinforce soft tissue for 6-9 months before absorbing ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... November 30, 2015 --> ... "Dental Lasers Market by Product (Soft Tissue, All Tissue, Dental ... (Hospitals, Clinics), and Geography - Global Forecast to 2020", published ... 2020, at a CAGR of 5.2% during the forecast period ... data Tables and 62 Figures spread through 167 P ...
(Date:11/30/2015)... 2015  PTS Diagnostics, the U.S.-based manufacturer of point-of-care ... A1CNow ® systems, and PTS Detect™ cotinine systems, ... that will propel the company into the mHealth market. ... Europe . The technology is a system that ... smartphones and tablets, and uses test strip technology already ...
(Date:11/30/2015)... Nov. 30, 2015 Oramed Pharmaceuticals Inc. (NASDAQ: ... the development of oral drug delivery systems, announced today ... at up to $50,000,000 with Hefei Tianhui Incubator of Technologies Co., Ltd. ... capsule, ORMD-0801, in China , ... . The agreements were signed at the Israel ...
Breaking Medicine Technology: